Basel, 08 February 2018 Roche purchases shares in tender offer for Ignyta, Inc. Roche (SIX: RO, ROG; OTCQX: RHHBY) and Ignyta, Inc. today announced that Roche’s wholly owned subsidiary Abingdon Acquisition Corp., has accepted for payment all shares validly tendered and not validly withdrawn pursuant to its tender offer for all outstanding shares of common... Read more
Basel, 08 February 2018 Roche purchases shares in tender offer for Ignyta, Inc. Roche (SIX: RO, ROG; OTCQX: RHHBY) and Ignyta, Inc. today announced that Roche’s wholly owned subsidiary Abingdon Acquisition Corp., has accepted for payment all shares validly tendered and not validly withdrawn pursuant to its tender offer for all outstanding shares of common... Read more
Basel, 06 February 2018 Reminder: Invitation to Roche’s Virtual Pipeline Event Phase 2 results of the bispecific VEGF/Ang2 antibody RG7716 in diabetic macula edema presented at Angiogenesis 2018 We are pleased to invite investors and analysts to participate in a live audio webcast and conference call on Tuesday, 13 February 2018. This is the first event... Read more
Basel, 06 February 2018 Reminder: Invitation to Roche’s Virtual Pipeline Event Phase 2 results of the bispecific VEGF/Ang2 antibody RG7716 in diabetic macula edema presented at Angiogenesis 2018 We are pleased to invite investors and analysts to participate in a live audio webcast and conference call on Tuesday, 13 February 2018. This is the first event... Read more
Basel, 06 February 2018 Phase III IMmotion151 study showed Roche’s TECENTRIQ® (atezolizumab) and Avastin® (bevacizumab) reduced the risk of disease worsening or death by 26 percent in certain people with advanced kidney cancer TECENTRIQ and Avastin met co-primary endpoint of improvement in investigator-assessed progression-free survival (PFS) compared with sunitinib for people whose disease expressed PD-L1... Read more
Basel, 06 February 2018 Phase III IMmotion151 study showed Roche’s TECENTRIQ® (atezolizumab) and Avastin® (bevacizumab) reduced the risk of disease worsening or death by 26 percent in certain people with advanced kidney cancer TECENTRIQ and Avastin met co-primary endpoint of improvement in investigator-assessed progression-free survival (PFS) compared with sunitinib for people whose disease expressed PD-L1... Read more
Basel, 06 February 2018 Phase III IMmotion151 study showed Roche’s TECENTRIQ® (atezolizumab) and Avastin® (bevacizumab) reduced the risk of disease worsening or death by 26 percent in certain people with advanced kidney cancer TECENTRIQ and Avastin met co-primary endpoint of improvement in investigator-assessed progression-free survival (PFS) compared with sunitinib for people whose disease expressed PD-L1... Read more
Basel, 06 February 2018 Phase III IMmotion151 study showed Roche’s TECENTRIQ® (atezolizumab) and Avastin® (bevacizumab) reduced the risk of disease worsening or death by 26 percent in certain people with advanced kidney cancer TECENTRIQ and Avastin met co-primary endpoint of improvement in investigator-assessed progression-free survival (PFS) compared with sunitinib for people whose disease expressed PD-L1... Read more
Basel, 29 January 2018 FDA grants Breakthrough Therapy Designation for Roche’s balovaptan in autism spectrum disorder Balovaptan has the potential to be the first pharmacotherapy to help improve core social interaction and communication in people with autism spectrum disorder Second FDA Breakthrough Therapy Designation for a Roche neuroscience medicine Roche (SIX: RO, ROG; OTCQX: RHHBY)... Read more
Basel, 26 January 2018 CHMP recommends EU approval of Roche’s Hemlibra for people with haemophilia A with inhibitors Hemlibra demonstrated superior efficacy compared to prior treatment with bypassing agents in two phase III studies across age groups With once-weekly subcutaneous (under the skin) administration, Hemlibra may help reduce the burden of managing haemophilia A Roche... Read more